Conference call interim report
Invitation to attend Vitrolife’s conference call regarding presentation of the interim report for the period January – March 2019. The presentation will be held in English.
Time: Tuesday April 23, 2019 at 10.00 a.m. CET.
Registration can preferably be done 10-15 minutes before the conference start time on:
Sweden dial in number: +46 (0)8 506 921 69
International dial in number: +44 (0) 203 0095709
Conference name: Vitrolife, conference ID: 8787698
Thomas Axelsson, CEO
Mikael Engblom, CFO
The press release for Vitrolife’s Report on Operations will be released at 8.30 CET on the same day.
Before the conference call, slides will be available at the company web page, https://www.vitrolife.com/investors/Presentations /
A recorded version of the presentation will be available for seven days on number
+44 (0) 333 300 9785 (International), access code 8787698.
Gothenburg, 11 April, 2019
VITROLIFE AB (publ)
For further information, please contact:
Mikael Engblom, CFO, +46 (0) 31 721 80 14
This is a translation of the Swedish version of the press release. When in doubt, the Swedish wording prevails.
Vitrolife is an international medical device Group. Vitrolife develops, produces and markets medical devices for assisted reproduction.
Vitrolife has approximately 390 employees and the company's products are sold in about 110 markets. The company is headquartered in Gothenburg, Sweden, and there are also offices in Australia, Belgium, China, Denmark, France, Germany, Italy, Japan, United Kingdom and USA. The Vitrolife share is listed on NASDAQ Stockholm.
Vitrolife AB (publ), Box 9080, SE-400 92 Göteborg, Sweden. Corporate identity number 556354-3452. Tel: 46 31 721 80 00. Fax: 46 31 721 80 99. E-mail: email@example.com. Website: www.vitrolife.com/